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Inﬂuence of Olmesartan on Heart Function in Patients with Chronic Congestive
Heart Failure
Guo Linlin, Wang Tao, Zhao Liang-Ge, Bu Xiao-Cui, Cao Guang-Zhi
The Afﬁliated Cardiovascular Hospital Of Medical College
Objectives: To study the effects 0f olmesartan in patients with chronic congestive
heart failure (CHF).
Methods: 120 patients with chronic congestive heart failure (II-IV) were randomly
assigned into two groups: Olmesartan group (Group I, n¼60), Valsartan group (Group
II, n¼60), regular therapy (cardiotonic, diuretic, aldosterone receptor antagonist, beta-
blockers and so on) were given to all patients, olmesartan and valsartan were sepa-
rately given to the two groups in addition to the regular therapy. Two groups of left
ventricular systolic dysfunction, ejection fraction, and NT-ProBNP were observed
before and after treatment in 8 weeks later.
Results: At Group I and II, there were signiﬁcant difference in the left ventricular end-
diastolic diameter (P<0.05), left ventricular ejection fraction (P<0.05) and the level of
NT-proBNP (P<0.01) before and after treatment, but there were no signiﬁcant dif-
ference between Group I and II after treatment (P>0.05).
Conclusions: Olmesartan and conventional heart failure therapy in patients with
chronic heart failure can effectively improve heart function, and not worse than
valsartan.
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Variety and clinical signiﬁcance of serum 2-oxoglutarate in chronic heart failure
Chen Pingan, Ding-Li Xu
Department of Cardiology, Nanfang Hospital, Southern Medical University,
Guangzhou, China
Objectives: Our goals were to test the hypotheses that whether the serum concen-
tration of 2-oxoglutarate is associated with the severity of chronic heart failure (CHF),
and to assess the predictive value of 2-oxoglutarate to the prognosis of CHF.
Methods: 219 CHF patients and 66 healthy controls were enrolled. Serum
2-oxoglutarate was assayed with Agilent 6460 LC/MS/MS. CHF patients were clas-
siﬁed into 4 groups according to the levels of NT-proBNP and NYHA classiﬁcation
respectively. Subjects were followed for death or recurrent hospital admission due to
CHF for the mean follow-up time 6.640.16 months.
Results: Serum 2-oxoglutarate was higher in CHF patients compared with controls
(P<0.01). Serum 2-oxoglutarate levels were lower in the group NYHA 1 than those in
the group NYHA 3 and 4. Compared with the group NYHA 3 and 4, the similar
results were found in the group NYHA 2. According to receiver operator characteristic
curve analysis, the optimal cut-off value of 2-oxoglutarate to predict severity of CHF
was over 19.732 mg/ml, (area under the curve 0.679, 95% CI 0.608-0.750). Kaplan-
Meier survival curves showed an association between high 2-oxoglutarate levels and
increased short adverse outcomes in CHF. Pearson correlation showed that Log
2-oxoglutarate was signiﬁcantly correlated with Log NT-proBNP (r¼0.283, P<0.01),
eGFR (r¼0.142, P¼0.036) and NYHA classiﬁcation (r¼0.284, P<0.01), inversely
correlated with age (r¼-0.269, P<0.01) and Log LVEF (r¼-0.192, P<0.01).
Conclusions: Serum 2-oxoglutarate was higher in CHF patients compared with
controls. The levels of serum 2-oxoglutarate can reﬂect the clinical severity of CHF.
Patients with low LVEF had high levels of 2-oxoglutarate. Serum 2-oxoglutarate also
can reﬂect the short-term outcome of CHF.
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A prospective study on autologous bone marrow mononuclear cell
transplantation in ischemic heart failure
Qin Jie1, Xiaoli Wang2, Mingjun Bai1, Shaohong Huang3, Jie Qin1
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of Sun Yat-sen University, Guangzhou 510630, China, 3Division of Cardiothoracic
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China
Objectives: To determine whether autologous bone marrow mononuclear cell
(ABMMC) transplantation for heart failure can improve left ventricular ejection
fraction (LVEF).
Methods: 110 ischemic heart failure patients were enrolled. After 4- to 12-week
pharmacotherapy optimization, 42 patients with LVEF 45% received injections of
ABMMC or vehicle intra-operatively into the myocardial infarction border area in a
randomized, double-blind manner.
Results: Myocardial scar size by magnetic resonance imaging (MRI) in injected
segments rose by 5.4% among controls (interquartile range [IQR]: -3.2-11.2), fell by
12.6% in the BMMC group (IQR: -22.4- -8.5) (P¼0.001).The median number of cells
injected was 8.6108 (IQR: 5.4108-14.5108). LVEF and myocardial scar size
were measured by MRI and viability was assessed by positron emission tomography
(PET), pre-operatively and after 1-year follow-up. LVEF improved by 5.4% in the
control group (IQR: 0.3-10.4) and by 4.9% in the ABMMC group (IQR 0.7-8.5)
(P¼0.56). Wall thickening in injected segments rose by 4.6% among controls (IQR
-18.4-24.6) and by 5.4% in the ABMMC group (IQR -8.6-25.5) (P¼0.58). Changes in
viability by PET were not signiﬁcantly different between groups.C182 JACC Vol 64/16/Suppl C j October 16–1Conclusions: ABMMC transplantation for heart failure can reduce myocardial scar
size, while failed to improve LVEF.
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History of left bundle branch block predicts clinical outcomes in patients with
dilated cardiomyopathy undergoing cardiac resynchronization therapy
Liang Yuanhong, Wu Shulin
Guangdong General Hospital, Department of Cardiology, Guangdong
Cardiovascular Institute
Objectives: This study to explore the clinical outcomes and predictor of cardiac
resynchronization therapy (CRT) in left bundle branch block patients with non-
ischemic dilated cardiomyopathy undergoing cardiac resynchronization therapy.
Methods: Twenty-seven LBBB patients with severe heart failure were treated with
CRT. Twenty-six LBBB patients without CRT served as control. During 6 months
follow-up, ECG, plasma NT-proBNP and echocardiogram including indexes left
ventricular end diastolic diameter (LVEDD), left ventricular end systolic volume
(LVESV), Mitral regurgitation area (MRA), left ventricular ejection fraction (LVEF)
were measured.
Results: Compared with baseline, NYHA functional class of 23 patients (85.2%) was
improved in CRT group. Compared with baseline and control, QRS duration
(QRSd) was signiﬁcantly more narrow (129.69.5 ms vs. 158.19.2 ms, P¼0.023;
129.69.5 ms vs. 161.311.2 ms, P¼0.019), NT-proBNP was signiﬁcantly lower
(P¼0.011, P¼0.009). Compared with control, LVEF, LVEDD, LVESV and MRA
were signiﬁcantly improved in CRT group (49.57.6 vs. 29.98.3 P<0.01;
539 mm vs. 6214 mm P<0.01; 16143.6 vs. 23755.6 P<0.01; 4.40.8 vs.
8.51.6 cm2 P<0.01). when the LBBB history was 2 years and QRSd 155 ms, the
sensitivity and speciﬁcity of CRT super-response were 53.4% and 85.6% respectively.
Conclusions: CRT can improve the synchronization and hemodynamic of LBBB
patients with nonischemic dilated cardiomyopathy, the LBBB history 2 years and
QRSd 155 ms are one of the CRT super-response predictors.
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Rhythm verse rate control in patients with atrial ﬁbrillation and heart failure:
An updated meta-analysis of randomized controlled trials
Shen Dongli, Guohui Zhang
Department of Cardiology, the afﬁliated People’s Hospital of Jiangsu University,
Zhenjiang, Jiangsu, China
Objectives: Several clinical studies showed inconsistent results of rhythm control in
patients with heart failure (HF) and atrial ﬁbrillation (AF). We hypothesized that
rhythm control had a better outcome than rate control in these patients.
Methods: PUBMED, EMBASE and the Cochrane Library were searched for ran-
domized controlled trials (RCTs). Statistical heterogeneity was assessed using I2
statistic and Cochran’s Q statistic. Risk ratio (RR) with 95% conﬁdence intervals (CIs)
were calculated to compare the all-cause mortality, hospitalizations, stroke or
thromboembolic events, and the quality of life and the change in LVEF were extracted
as weighted mean differences (WMD) and 95% CIs between rate control and rhythm
control.
Results: Eight RCTs with 2783 patients were included in the analysis. Rhythm control
had no advantages on all-cause mortality (RR 0.67; 95% CI 0.43-1.05, P¼0.08) or
stroke/thromboembolic events (RR 0.89; 95% CI 0.59-1.37, P¼0.61), but higher risk
of hospitalization (RR 1.09, 95% CI 1.02-1.16, P¼0.01) compared with rate control
strategy. However, rhythm control strategy might improve the LVEF (WMD 7.64;
95% CI 5.17-10.11, P<0.001) and the quality of life (WMD -8.21; 95% CI -11.24-
5.19, P<0.001) in patients with AF and HF.
Conclusions: The present analysis suggests that rhythm control strategy might
improve the LVEF and quality of life in patients with AF and HF. However, there was
no sufﬁcient evidence to support the advantages of rhythm control strategy on hos-
pitalization, stroke/thromboembolic events, or all-cause mortality.
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Hemodynamic effects of short-term infusion of recombinant human atrial
natriuretic peptide (rhANP) for congestive heart failure: a randomized,
double-blind, placebo-controlled study
Wang Pengbo1, Huang Jie1, Tan Huiqiong1, Liu Wenxian2, Zhang Jian1,
Liao Zhongkai1, Yu Litian1, Mao Yi1, Ye Shaodong1, Feng Lei1, Zhang Yuhui1,
Wang Yang1, Li Wei1, Luan Xiaojun1, Wang Sijia1, Bai Shugong2, Wang Guogan1
1Fu Wai Hospital, 2Anzhen Hospital
Objectives: This study was designed to conﬁrm hemodynamic effects of short-term
infusion of recombinant human atrial natriuretic peptide (rhANP) at the prespeciﬁed
dose in patients with congestive heart failure compared to placebo when both were
added to standard care.
Methods: After the placement of a Swan-Ganz catheter, 121 patients with a pulmo-
nary-capillary wedge pressure (PCWP) of 13 mmHg or higher were randomly
assigned to double-blind treatment with placebo or rhANP (initiated at a rate of
0.1mg/kg/min, adjusted to 0.15 mg/kg/min half an hour later if the systolic blood
pressure was more than 100 mmHg and the PCWP was 15 mmHg or higher, and
stopped one hour later from the initiation). The hemodyamic parameters were9, 2014 j GW-ICC Abstracts/Cardiovascular Disease Clinical Research
